Hidehiro Ishikawa

Dr. Hidehiro Ishikawa


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
KMKeita Matsuura
Keita Matsuura
YIYuichiro Ii
Yuichiro Ii
MMMasayuki Maeda
Masayuki Maeda
KTKen-Ichi Tabei
Ken-Ichi Tabei
MSMasayuki Satoh
Masayuki Satoh
HTHidekazu Tomimoto
Hidekazu Tomimoto

30 June 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
TKTakayuki Kondo
Takayuki Kondo
HBHaruhiko Banno
Haruhiko Banno
TOTaro Okunomiya
Taro Okunomiya
YAYoko Amino
Yoko Amino
KEKayoko Endo
Kayoko Endo
HIHaruhisa Inoue
Haruhisa Inoue
Introduction Alzheimer’s disease (AD) is one of the most common causes of dementia. Pathogenic variants in the presenilin 1 (PSEN1) gene are the most frequent cause of early-onset AD. Medications for patients with AD bearing PSEN1 mutation (PSEN1-AD) are limited to symptomatic therapies and no established radical treatments are available. Induced pluripotent stem cell (iPSC)-based drug repurposing identified bromocriptine as a therapeutic candidate for PSEN1-AD. In this study, we used an enrichment strategy with iPSCs to select the study population, and we will investigate the safety and efficacy of an orally administered dose of bromocriptine in patients with PSEN1-AD. Methods and analysis This is a multicentre, randomised, placebo-controlled trial. AD patients with PSEN1 mutations and a Mini Mental State Examination-Japanese score of ≤25 will be randomly assigned, at a 2:1 ratio, to the trial drug or placebo group (≥4 patients in TW-012R and ≥2 patients in placebo). This clinical trial consists of a screening period, double-blind phase (9 months) and extension phase (3 months). The double-blind phase for evaluating the efficacy and safety is composed of the low-dose maintenance period (10 mg/day), high-dose maintenance period (22.5 mg/day) and tapering period of the trial drug. Additionally, there is an open-labelled active drug extension period for evaluating long-term safety. Primary outcomes are safety and efficacy in cognitive and psychological function. Also, exploratory investigations for the efficacy of bromocriptine by neurological scores and biomarkers will be conducted. Ethics and dissemination The proposed trial is conducted according to the Declaration of Helsinki, and was approved by the Institutional Review Board (K070). The study results are expected to be disseminated at international or national conferences and published in international journals following the peer-review process. Trial registration number jRCT2041200008, NCT04413344.

6 August 2015 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
HIHidehiro Ishikawa
Hidehiro Ishikawa
NKN. Kawada
N. Kawada
ATA. Taniguchi
A. Taniguchi
KOK. Odachi
K. Odachi
AMA. Mizutani
A. Mizutani
HTH. Tomimoto
H. Tomimoto
Background Paraneoplastic neurological syndromes (PNS) are rare remote effect of cancer. The antibodies and tumors associated with PNS have been well described, but there are still many clinically suspected cases in which no tumor or antibody can be identified. This is the first report of PNS showing hot cross‐bun sign and caused by exceptionally rare underlying malignancy, such as burned‐out testicular tumor. Case presentation A 42‐year‐old man presented subacute progression of hearing loss and cerebellar ataxia. Cerebrospinal fluid showed continuous inflammation and magnetic resonance imaging (MRI) revealed cerebellar atrophy and hot cross‐bun sign. Resection of tumors improved both laboratory findings and neurological signs and their pathology was seminoma. Conclusion Seminoma can cause PNS showing 8th cranial nerve palsy, cerebellar, and brainstem atrophy with hot cross‐bun sign on MRI study. Extensive screening for onconeural antibodies was negative and thereby suggested that unknown antibodies worked for both antitumor immunity and induction of PNS.

24 September 2021 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
HIHidehiro Ishikawa
Hidehiro Ishikawa
CMCaleigh Mandel‐Brehm
Caleigh Mandel‐Brehm
ASAkihiro Shindo
Akihiro Shindo
MCMartha A. Cady
Martha A. Cady
SMSabrina A. Mann
Sabrina A. Mann
HTHidekazu Tomimoto
Hidekazu Tomimoto

8 April 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
KMKana Matsuda
Kana Matsuda
ASAkihiro Shindo
Akihiro Shindo
YIYuichiro Ii
Yuichiro Ii
KTKen-Ichi Tabei
Ken-Ichi Tabei
YUYukito Ueda
Yukito Ueda
HTHidekazu Tomimoto
Hidekazu Tomimoto
Objective: The severity of cerebral small vessel disease (SVD) is assessed through neuroimaging findings, including hypertensive arteriopathy (HA)-SVD and cerebral amyloid angiopathy (CAA)-SVD. HA-SVD and CAA-SVD have been collectively estimated as total scores: the HA-SVD and CAA-SVD scores, respectively. Previous reports suggest that HA-SVD scores are associated with cognitive function; however, the relationship between CAA-SVD scores and cognitive function remains unclear. Therefore, we examined the association between CAA-SVD scores and cognitive function. Furthermore, we developed a modified CAA-SVD score considering cortical microinfarcts and posterior dominant white matter hyperintensities, which are imaging findings of CAA, and examined the association between these scores and cognitive function in the same patient group. Design: Prospective study. Setting: Single centre study from a memory clinic. Participants: Subjects were diagnosed with mild cognitive impairment (MCI) or mild dementia in our memory clinic between February 2017 and July 2019 and underwent clinical dementia rating scale and brain MRI assessment. A total of 42 patients (aged 75.3±9.12 years) were registered prospectively. Primary and secondary outcome measures: We evaluated intellectual function, memory, frontal lobe function and constructional ability. Furthermore, the relationship between each score and cognitive function was examined. Results: The CAA-SVD score showed significant associations with cognitive function (R 2 =0.63, p=0.016), but the HA-SVD score did not (R 2 =0.41, p=0.35). The modified CAA-SVD score was also significantly associated with cognitive function (R 2 =0.65, p=0.008). Conclusion: Cognitive function is associated with the CAA-SVD score, and more efficiently with the modified CAA-SVD score, in memory clinic patients. Although we have not validated the weighting of the modified CAA-SVD score, these scores can be a predictor of cognitive deterioration in patients with MCI and mild dementia.

17 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
HMHirofumi Matsuyama
Hirofumi Matsuyama
KMKeita Matsuura
Keita Matsuura
HIHidehiro Ishikawa
Hidehiro Ishikawa
YHYoshinori Hirata
Yoshinori Hirata
NKNatsuko Kato
Natsuko Kato
HTHidekazu Tomimoto
Hidekazu Tomimoto
Long-term intake of potential zinc-chelating drugs may cause zinc deficiency. We postulated that zinc deficiency in Parkinson’s disease (PD) patients was related to the intake of drugs such as levodopa. We investigated the relationship between zinc levels and levodopa administration period, dosage, and symptoms of zinc deficiency in PD patients. We measured serum zinc levels and analyzed correlations between serum zinc levels, the levodopa oral administration period, dosage, dosing frequency, and zinc deficiency symptoms including taste disorders. Data analyses were performed using Spearman’s rank correlation coefficient. The mean serum zinc level was 60.5 ± 11.6 μg/dL. The mean administration period for levodopa was 8.0 ± 5.5 years, mean administration frequency 3.4 ± 0.9 times/d, and mean administration dose 420.6 ± 237.1 mg/d. Negative correlations between zinc levels and levodopa dosage and dosing frequency were found. Multiple regression analysis showed a significant correlation with the frequency of levodopa (β = −0.360, p = 0.007). No significant change in clinical symptoms was observed after zinc administration, but anxiety tended to improve. Our results indicated that frequent levodopa administration strongly influenced serum zinc levels which may have alleviating effects on psychiatric symptoms; therefore, preventing zinc deficiency can be important during PD treatment.